Education
About Us
Working with TipRanks
Follow Us
BiomX (PHGE)
:PHGE
PHGE Stock Chart & Stats
$5.72
-$0.09(-11.33%)
At close: 4:00 PM EST
$5.72
-$0.09(-11.33%)
Day’s Range― - ―
52-Week Range$1.50 - $22.04
Previous CloseN/A
Volume30.96K
Average Volume (3M)1.32M
Market Cap
$8.73M
Enterprise Value$7.41M
Total Cash (Recent Filing)$7.91M
Total Debt (Recent Filing)$6.58M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Apr 01, 2026EPS Estimate
-5.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.51
Shares Outstanding1,526,640
10 Day Avg. Volume1,108,900
30 Day Avg. Volume1,322,820
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.11
Price to Sales (P/S)0.00
P/FCF Ratio-1.38
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-25.37
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$26.00Price Target Upside354.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ContinuationIndependent data monitoring committee recommended continuation of the cystic fibrosis study with protocol amendments, enabling the program to proceed while addressing observed adverse events.
Enrollment And Commercial OpportunityEuropean enrollment progressing ahead of plan and the strategic pivot to diabetic foot infections point to a larger patient population and improved commercial potential for the pipeline shift to BX011.
Regulatory Support For BX011Positive FDA feedback supports advancing the fixed multi‑phage cocktail BX011 into a Phase 2a diabetic foot infection study and provides clearer guidance on trial design.
Bears Say
Delayed Data TimelineA shift to a later topline cystic fibrosis data date increases uncertainty around clinical milestones and could weigh on investor confidence.
Financing And Liquidity RiskSecuring financing is identified as a company priority, indicating elevated funding needs that could pressure liquidity and raise dilution risk for shareholders.
Regulatory Hold Tied To Third‑party DeviceFDA questions about a third‑party nebulizer have prompted a U.S. hold on the cystic fibrosis study, creating regulatory uncertainty related to external device partners.
BiomX News
PHGE FAQ
What was BiomX’s price range in the past 12 months?
BiomX lowest stock price was $1.50 and its highest was $22.04 in the past 12 months.
What is BiomX’s market cap?
BiomX’s market cap is $8.73M.
When is BiomX’s upcoming earnings report date?
BiomX’s upcoming earnings report date is Apr 01, 2026 which is in 58 days.
How were BiomX’s earnings last quarter?
BiomX released its earnings results on Nov 12, 2025. The company reported -$5.51 earnings per share for the quarter, beating the consensus estimate of -$5.605 by $0.095.
Is BiomX overvalued?
According to Wall Street analysts BiomX’s price is currently Undervalued.
Does BiomX pay dividends?
BiomX does not currently pay dividends.
What is BiomX’s EPS estimate?
BiomX’s EPS estimate is -5.06.
How many shares outstanding does BiomX have?
BiomX has 1,526,640 shares outstanding.
What happened to BiomX’s price movement after its last earnings report?
BiomX reported an EPS of -$5.51 in its last earnings report, beating expectations of -$5.605. Following the earnings report the stock price went down -1.92%.
Which hedge fund is a major shareholder of BiomX?
Currently, no hedge funds are holding shares in PHGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BiomX
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
PHGE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and positive regulatory feedback which provides a strong outlook for future developments. However, financial challenges and regulatory holds present ongoing risks. Optimism in phage therapy's future and strategic plans for BX011 and BX004 suggest a cautiously positive sentiment.View all PHGE earnings summariesPHGE Stock 12 Month Forecast
Average Price Target
$26.00
▲(354.55% Upside)